Dr. Venkatraman brings over 25 years of experience in small molecule and Biologics drug development, manufacturing, and advancing strategic growth initiatives
During this quarter, the company achieved a key milestone of reaching 1,000 DCGI approvals
The transaction aligns with Aurobindo’s strategic objective to expand its U.S. manufacturing footprint by enhancing its existing domestic capabilities
His experience includes leadership roles in manufacturing, strategic management, and commercial operations across the pharmaceuticals, healthcare, and specialty chemicals sectors
The site, spanning approximately 25,000 square meters, is expected to commence operations by the end of 2025
Enhanced alignment to better serve customers across the entire drug development lifecycle under the Fujifilm Life Sciences brand umbrella with the tagline Partners for Life
Akums invested Rs. 272 crore in capital expenditure during FY25
The CDMO upgrade represents a transformational step for Remedium Lifecare
PAT stood at Rs. 88 crore for Q4 FY25 as compared to Rs. 56 crore in Q4FY24, an increase of 57%
Subscribe To Our Newsletter & Stay Updated
